Chihiro Fushimi

Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Salivary Duct Carcinoma

Hideaki Takahashi, Yuichiro Tada, Takashi Saotome et al. · Journal of Clinical Oncology · 2018 · 246 citations

Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma

Tatsuo Masubuchi, Yuichiro Tada, Shin-ichiro Maruya et al. · International Journal of Clinical Oncology · 2014 · 114 citations

Androgen Receptor, Clinicopathological Significance, Endocrine-related Cancer +9

Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification

Soichiro Takase, Satoshi Kano, Yuichiro Tada et al. · Oncotarget · 2017 · 110 citations · Full text

Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma

Kazutomo Niwa, Daisuke Kawakita, Toshitaka Nagao et al. · Scientific Reports · 2020 · 56 citations · Full text

Efficacy and safety of nivolumab in 100 patients with recurrent or metastatic head and neck cancer – a retrospective multicentre study

Isaku Okamoto, Hiroki Sato, Takahito Kondo et al. · Acta Oto-Laryngologica · 2019 · 50 citations